Vestal Point Capital, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001974915
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 72 positions · Total reported value $1.90B · Top-10 concentration 45.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 64.6% · 14 new · 20 cut · 19 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2025 13F filing, Vestal Point Capital, LP disclosed 72 equity positions with a combined reported value of $1.90B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were ACLX ($181.09M), JAZZ ($127.34M), CYTK ($98.29M). By sector, the heaviest allocations are Health Care 69.4%, Industrials 2.1%. Versus the prior quarter, allocation shifted toward Health Care (+5.1pp) and away from Industrials (-0.6pp), Other (-4.6pp).
Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 59% of names.
The largest new positions opened in Q2 2025 were JAZZ ($127.34M), ALC ($46.35M), RVMD ($44.15M).
Of the 19 positions fully exited versus the prior quarter, the largest were INSM ($82.01M), URGN ($23.81M), RARE ($18.11M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
- JAZZ JAZZ PHARMACEUTICALS PLC · $127.34M
- ALC ALCON AG · $46.35M
- RVMD REVOLUTION MEDICINES INC · $44.15M
- EXAS EXACT SCIENCES CORP COM · $37.20M
- BMRN BIOMARIN PHARMACEUTICAL INC · $27.48M
- COO COOPER COS INC · $24.91M
- ABT ABBOTT LABORATORIES · $23.80M
- EW EDWARDS LIFESCIENCES CORP · $23.46M
Fully Exited (vs previous quarter)
- INSM INSMED INC · prev qtr: $82.01M · history
- URGN UROGEN PHARMA LTD · prev qtr: $23.81M
- RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $18.11M
- LQDA LIQUIDIA CORPORATION · prev qtr: $18.10M
- ESTA ESTABLISHMENT LABS HLDGS INC · prev qtr: $17.68M
- VRNA VERONA PHARMA PLC · prev qtr: $16.99M
- SRPT SAREPTA THERAPEUTICS INC · prev qtr: $12.76M
- IMVT IMMUNOVANT INC · prev qtr: $5.98M
Insider Transactions (Form 4)
Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-127682 (status: Approved), registered 2023-04-14
- Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: vestalpoint.com
Portfolio Structure
- 63 positions · $3.87B reported value (Q3 2026)
- Top 10 holdings = 67.3% of reported value
- Largest position: ABVX (ABIVAX SA) at 10.1%
- Average position size: $61.44M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.75M | $181.09M | 9.53% | Add | |
| 2 |
|
1.20M | $127.34M | 6.71% | New | |
| 3 |
|
2.98M | $98.29M | 5.17% | Add | |
| 4 |
|
1.07M | $82.02M | 4.32% | Hold | |
| 5 |
|
3.10M | $73.04M | 3.85% | Add | |
| 6 |
|
11.90M | $68.19M | 3.59% | Add | |
| 7 |
|
2.00M | $62.60M | 3.30% | Add | |
| 8 |
|
3.20M | $59.62M | 3.14% | Add | |
| 9 |
|
1.50M | $53.13M | 2.80% | Add | |
| 10 |
|
4.67M | $52.85M | 2.78% | Reduce | |
| 11 |
|
700.00K | $51.85M | 2.73% | Add | |
| 12 |
|
3.70M | $51.58M | 2.72% | Reduce | |
| 13 |
|
5.00M | $46.45M | 2.45% | Add | |
| 14 |
|
525.00K | $46.35M | 2.44% | New | |
| 15 |
|
1.20M | $44.15M | 2.32% | New | |
| 16 |
|
1.50M | $43.14M | 2.27% | Hold | |
| 17 |
|
700.00K | $37.20M | 1.96% | New | |
| 18 |
|
1.75M | $35.61M | 1.88% | Add | |
| 19 |
|
200.00K | $34.52M | 1.82% | Add | |
| 20 |
|
6.25M | $33.62M | 1.77% | Reduce | |
| 21 |
|
23.77M | $33.52M | 1.76% | Add | |
| 22 |
|
500.00K | $29.51M | 1.55% | Add | |
| 23 |
|
500.00K | $27.48M | 1.45% | New | |
| 24 |
|
550.00K | $25.96M | 1.37% | Add | |
| 25 |
|
2.65M | $25.41M | 1.34% | Reduce | |
| 26 |
|
11.02M | $25.11M | 1.32% | Hold | |
| 27 |
|
350.00K | $24.91M | 1.31% | New | |
| 28 |
|
1.20M | $24.89M | 1.31% | Reduce | |
| 29 |
|
500.00K | $24.36M | 1.28% | Reduce | |
| 30 |
|
4.52M | $24.24M | 1.28% | Add | |
| 31 |
|
175.00K | $23.80M | 1.25% | New | |
| 32 |
|
300.00K | $23.46M | 1.24% | New | |
| 33 |
|
2.00M | $22.78M | 1.20% | Add | |
| 34 |
|
3.08M | $22.11M | 1.16% | Add | |
| 35 |
|
500.00K | $20.60M | 1.08% | Add | |
| 36 |
|
500.00K | $19.75M | 1.04% | New | |
| 37 |
|
3.00M | $19.50M | 1.03% | Add | |
| 38 |
|
195.00K | $17.00M | 0.90% | New | |
| 39 |
|
625.00K | $16.70M | 0.88% | Add | |
| 40 |
|
1.15M | $14.43M | 0.76% | Add | |
| 41 |
|
5.60M | $13.89M | 0.73% | Hold | |
| 42 |
|
3.23M | $12.98M | 0.68% | Add | |
| 43 |
|
1.40M | $10.49M | 0.55% | Reduce | |
| 44 |
|
25.00K | $10.14M | 0.53% | New | |
| 45 |
|
50.00K | $9.88M | 0.52% | Reduce | |
| 46 |
|
550.00K | $8.01M | 0.42% | New | |
| 47 |
|
140.00K | $7.41M | 0.39% | New | |
| 48 |
|
1.50M | $7.33M | 0.39% | Reduce | |
| 49 |
|
3.00M | $6.93M | 0.36% | New | |
| 50 |
|
727.50K | $6.93M | 0.36% | Reduce | |
FAQ
What did Vestal Point Capital, LP buy in 2025-Q2?
In its 2025-Q2 13F filing, Vestal Point Capital, LP reported 72 equity positions worth $1.90B in aggregate; its largest disclosed positions were ACLX ($181.09M), JAZZ ($127.34M), CYTK ($98.29M).
How large is Vestal Point Capital, LP's portfolio?
Vestal Point Capital, LP reported $1.90B of long equity holdings across 72 positions as of 2025-Q2. Top-10 holdings account for 45.2% of reported value.
What is Vestal Point Capital, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.